Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast
Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company known for its patented diagnostic test development platform, has scheduled its first quarter 2025 earnings release for Thursday, May 8, 2025, after market close.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Key executives participating include:
- Dwight Egan - Chief Executive Officer
- Brian Brown - Chief Financial Officer
- Andrew Benson - Head of Investor Relations
Investors and analysts can access the event through:
- Webcast: Available on ir.codiagnostics.com (Events & Webcasts page)
- Conference Call: Toll-free (800-715-9871) or Toll (646-307-1963)
- Passcode: 1977478
A recording will be available on the company's website for those unable to attend the live session.
Co-Diagnostics (NASDAQ: CODX), azienda di diagnostica molecolare nota per la sua piattaforma brevettata di sviluppo di test diagnostici, ha programmato la pubblicazione dei risultati del primo trimestre 2025 per giovedì 8 maggio 2025, dopo la chiusura del mercato.
La società terrà una conference call e una webcasting alle 16:30 ET dello stesso giorno. I principali dirigenti partecipanti saranno:
- Dwight Egan - Amministratore Delegato
- Brian Brown - Direttore Finanziario
- Andrew Benson - Responsabile delle Relazioni con gli Investitori
Investitori e analisti potranno seguire l’evento tramite:
- Webcast: disponibile su ir.codiagnostics.com (pagina Eventi e Webcast)
- Conference Call: numero verde (800-715-9871) o numero locale (646-307-1963)
- Codice d’accesso: 1977478
La registrazione sarà disponibile sul sito web della società per chi non potesse partecipare in diretta.
Co-Diagnostics (NASDAQ: CODX), una empresa de diagnóstico molecular reconocida por su plataforma patentada para el desarrollo de pruebas diagnósticas, ha programado la publicación de resultados del primer trimestre de 2025 para el jueves 8 de mayo de 2025, después del cierre del mercado.
La compañía realizará una llamada en conferencia y una transmisión en vivo a las 4:30 p.m. ET del mismo día. Los principales ejecutivos participantes incluyen:
- Dwight Egan - Director Ejecutivo
- Brian Brown - Director Financiero
- Andrew Benson - Jefe de Relaciones con Inversionistas
Los inversores y analistas podrán acceder al evento a través de:
- Transmisión en vivo: disponible en ir.codiagnostics.com (página de Eventos y Webcasts)
- Llamada en conferencia: número gratuito (800-715-9871) o número local (646-307-1963)
- Código de acceso: 1977478
Quienes no puedan asistir en vivo podrán escuchar la grabación disponible en el sitio web de la compañía.
Co-Diagnostics (NASDAQ: CODX)는 특허받은 진단 테스트 개발 플랫폼으로 알려진 분자 진단 회사로, 2025년 1분기 실적 발표를 2025년 5월 8일 목요일 장 마감 후에 예정했습니다.
회사는 같은 날 오후 4시 30분(동부시간)에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 주요 임원진은 다음과 같습니다:
- 드와이트 이건 - 최고경영자(CEO)
- 브라이언 브라운 - 최고재무책임자(CFO)
- 앤드류 벤슨 - 투자자 관계 책임자
투자자와 애널리스트는 다음 방법으로 행사에 참여할 수 있습니다:
- 웹캐스트: ir.codiagnostics.com (이벤트 및 웹캐스트 페이지)에서 이용 가능
- 컨퍼런스 콜: 무료 전화 (800-715-9871) 또는 유료 전화 (646-307-1963)
- 접속 코드: 1977478
라이브 참석이 어려운 경우 회사 웹사이트에서 녹음본을 들을 수 있습니다.
Co-Diagnostics (NASDAQ: CODX), une société de diagnostic moléculaire reconnue pour sa plateforme brevetée de développement de tests diagnostiques, a programmé la publication de ses résultats du premier trimestre 2025 pour le jeudi 8 mai 2025, après la clôture du marché.
La société organisera une conférence téléphonique et une webdiffusion à 16h30 ET le même jour. Les principaux dirigeants participants sont :
- Dwight Egan - Directeur général
- Brian Brown - Directeur financier
- Andrew Benson - Responsable des relations investisseurs
Les investisseurs et analystes pourront accéder à l'événement via :
- Webdiffusion : disponible sur ir.codiagnostics.com (page Événements & Webcasts)
- Conférence téléphonique : numéro gratuit (800-715-9871) ou numéro local (646-307-1963)
- Code d'accès : 1977478
Un enregistrement sera disponible sur le site de la société pour ceux qui ne pourront pas assister en direct.
Co-Diagnostics (NASDAQ: CODX), ein Unternehmen für molekulare Diagnostik, bekannt für seine patentierte Plattform zur Entwicklung diagnostischer Tests, hat die Veröffentlichung der Ergebnisse für das erste Quartal 2025 für Donnerstag, den 8. Mai 2025, nach Börsenschluss geplant.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und Webcast abhalten. Wichtige teilnehmende Führungskräfte sind:
- Dwight Egan - Geschäftsführer (CEO)
- Brian Brown - Finanzvorstand (CFO)
- Andrew Benson - Leiter Investor Relations
Investoren und Analysten können die Veranstaltung über folgende Wege verfolgen:
- Webcast: Verfügbar auf ir.codiagnostics.com (Seite Veranstaltungen & Webcasts)
- Telefonkonferenz: gebührenfrei (800-715-9871) oder gebührenpflichtig (646-307-1963)
- Zugangscode: 1977478
Eine Aufzeichnung wird auf der Website des Unternehmens für diejenigen bereitgestellt, die nicht live teilnehmen können.
- None.
- None.
SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
The conference call and webcast will be available via:
Webcast: ir.codiagnostics.com on the Events & Webcasts page, or accessible directly here
Conference Call: 800-715-9871 (Toll Free) or (646) 307-1963 (Toll) with participant passcode 1977478
If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.
Investor Relations Contact:
Andrew Benson
Head of Investor Relations
+1 801-438-1036
investors@codiagnostics.com
FAQ
When will Co-Diagnostics (CODX) release Q1 2025 earnings?
How can investors join Co-Diagnostics Q1 2025 earnings call?
What time is CODX earnings call on May 8, 2025?
Can I listen to CODX Q1 2025 earnings call recording later?
Which executives will present at Co-Diagnostics Q1 2025 earnings call?
